利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

97 条记录 (耗时 0.1 秒)

    Active stylus
    41.
    外观设计
    Active stylus 有权

    公开(公告)号：USD909377S1

    公开(公告)日：2021-02-02

    申请号：US29696189

    申请日：2019-06-26

    申请人： Ling Huang

    设计人： Ling Huang

    FcγRIIB—specific antibodies and methods of use thereof
    44.
    发明授权
    FcγRIIB—specific antibodies and methods of use thereof 有权
    FcγRIIB特异性抗体及其使用方法

    公开(公告)号：US08785599B2

    公开(公告)日：2014-07-22

    申请号：US11768852

    申请日：2007-06-26

    申请人： Leslie S. Johnson ,  Ling Huang ,  Robyn Gerena

    发明人： Leslie S. Johnson ,  Ling Huang ,  Robyn Gerena

    IPC分类号： C07K16/00 ,  C12P21/08 ,  A61K39/395 ,  A61K39/40 ,  C07K1/00

    CPC分类号： C07K16/283 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/92

    摘要： The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than the antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also provides the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.

    摘要翻译： 本发明涉及以比抗体或其片段更大的亲和力结合FcγRIIA，特别是人FcγRIIA的FcγRIIB特别是人FcγRIIB特异性结合的抗体或其片段。 本发明还提供抗FcγRIIB抗体或其抗原结合片段作为治疗，预防，治疗或改善癌症，优选B细胞恶性肿瘤，特别是B细胞恶性肿瘤的单一药物治疗的用途 细胞性慢性淋巴细胞白血病或非霍奇金淋巴瘤，自身免疫性疾病，炎症性疾病，IgE介导的过敏性疾病或其一种或多种症状。 本发明提供了通过施用本发明的抗体来增强治疗性抗体的效应功能来增强治疗性抗体的治疗效果的方法。 本发明还提供了通过施用本发明的抗体来增强疫苗组合物的功效的方法。

    BCR-Complex-Specific Antibodies and Methods of Using Same
    45.
    发明申请
    BCR-Complex-Specific Antibodies and Methods of Using Same 有权
    BCR-复合物特异性抗体及其使用方法

    公开(公告)号：US20140017237A1

    公开(公告)日：2014-01-16

    申请号：US14034433

    申请日：2013-09-23

    申请人： Leslie S. Johnson ,  ling Huang

    发明人： Leslie S. Johnson ,  Ling Huang

    IPC分类号： C07K16/28

    CPC分类号： C07K16/28 ,  C07K16/2803 ,  C07K2317/24 ,  C07K2317/56

    摘要： This invention relates to chimeric and humanized antibodies that specifically bind the BCR complex, and particularly chimeric and humanized antibodies to the BCR complex. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.

    摘要翻译： 本发明涉及特异性结合BCR复合物的嵌合和人源化抗体，特别是涉及BCR复合物的嵌合和人源化抗体。 本发明还涉及将抗体及其组合物用于诊断，预后和治疗诸如癌症，自身免疫性疾病，炎症性疾病和感染性疾病的疾病的方法。

    Identification and engineering of antibodies with variant Fc regions and methods of using same
    47.
    发明授权
    Identification and engineering of antibodies with variant Fc regions and methods of using same 有权
    具有变体Fc区的抗体的鉴定和工程及其使用方法

    公开(公告)号：US08445645B2

    公开(公告)日：2013-05-21

    申请号：US13158169

    申请日：2011-06-10

    申请人： Jeffrey Stavenhagen ,  Sujata Vijh ,  Christopher Rankin ,  Sergey Gorlatov ,  Ling Huang

    发明人： Jeffrey Stavenhagen ,  Sujata Vijh ,  Christopher Rankin ,  Sergey Gorlatov ,  Ling Huang

    IPC分类号： C07K16/00 ,  C12P21/08 ,  A61K39/395 ,  A61K39/40

    CPC分类号： A61K39/39558 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/005 ,  C07K2317/52 ,  C07K2317/732 ,  C07K2317/734

    摘要： The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by FcγR is desired, e.g., cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

    摘要翻译： 本发明涉及包括变体Fc区的分子，特别是多肽，更特别是免疫球蛋白（例如，抗体），其中所述变体Fc区相对于野生型Fc区包含至少一个氨基酸修饰，所述变体Fc区 相对于包含野生型Fc区的可比较分子，以更大的亲和力结合FcγRIIIA和/或FcγRIIA。 本发明的分子特别可用于预防，治疗或改善与疾病，病症或感染相关的一种或多种症状。 本发明的分子特别可用于治疗或预防需要通过FcγAMR介导的效应细胞功能增强的功效（例如ADCC）的疾病或病症，例如癌症，感染性疾病和增强治疗功效 的治疗性抗体，其作用由ADCC介导。

    HUMANIZED ANTIBODIES AGAINST WEST NILE VIRUS AND THERAPEUTIC AND PROPHYLACTIC USES THEREOF
    49.
    发明申请
    HUMANIZED ANTIBODIES AGAINST WEST NILE VIRUS AND THERAPEUTIC AND PROPHYLACTIC USES THEREOF 审中-公开
    抗西兰病毒的人类抗体及其治疗和预防用途

    公开(公告)号：US20120070429A1

    公开(公告)日：2012-03-22

    申请号：US13214975

    申请日：2011-08-22

    申请人： Leslie S. Johnson ,  Ling Huang

    发明人： Leslie S. Johnson ,  Ling Huang

    IPC分类号： A61K39/395 ,  A61P31/12

    CPC分类号： C07K16/1081 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/567 ,  G01N33/56983 ,  G01N2333/18 ,  G01N2469/20 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/394 ,  Y02A50/396 ,  Y02A50/53 ,  Y02A50/60

    摘要： The present invention relates to compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV) and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV) infection utilizing said compositions. In particular, the present invention relates to methods for preventing, treating or ameliorating symptoms associated with WNV infection, said methods comprising administering to a human subject an effective amount of one or more humanized antibodies or fragments thereof that immunospecifically bind to a WNV antigen. The present invention also relates to detectable or diagnostic compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to a WNV antigen and methods for detecting or diagnosing WNV infection utilizing said compositions.

    摘要翻译： 本发明涉及包含人源化抗体或其片段的组合物，其免疫特异性结合黄病毒，特别是西尼罗病毒（WNV）的一种或多种抗原，以及用于预防，治疗或改善与黄病毒特别是西尼罗病毒有关的症状的方法 利用所述组合物的病毒（WNV）感染。 特别地，本发明涉及用于预防，治疗或改善与WNV感染相关的症状的方法，所述方法包括向人类受试者施用有效量的一种或多种免疫特异性结合WNV抗原的人源化抗体或其片段。 本发明还涉及包含免疫特异性结合WNV抗原的人源化抗体或其片段的可检测或诊断组合物，以及利用所述组合物检测或诊断WNV感染的方法。